15.4 Renal Failure, Dialysis Indications & Renal Transplantation

Renal Failure, Dialysis Indications, Transplantation & Complications

Renal failure and renal transplantation represent fundamental domains of urological practice tested extensively on the European Board of Urology (FEBU) examination. A competent urologist must command the etiological work-up of acute kidney injury (AKI), the systematic evaluation of oliguria and anuria, diagnostic differentiation among pre-renal, intrinsic parenchymal, and post-renal obstructive failure, evidence-based management of post-obstructive diuresis, and immediate recognition of life-threatening indications for urgent renal replacement therapy (the classic AEIOU criteria) per ETR Urology (pp. 40–41). Furthermore, mastery of surgical donor-recipient implantation anatomy, immunosuppressive protocols, calcineurin inhibitor nephrotoxicity, and the diagnostic salvage of post-transplant urological and vascular emergencies per European Association of Urology (EAU) Guidelines on Renal Transplantation is essential for clinical excellence.

---

1. Renal Failure Work-up & Acute Kidney Injury (AKI)

KDIGO Definition & Staging System

The Kidney Disease: Improving Global Outcomes (KDIGO) consensus criteria define Acute Kidney Injury (AKI) as any of the following:

1. Increase in serum creatinine by $\ge 26.5\ \mu\text{mol/L}$ ($\ge 0.3\text{ mg/dL}$) within 48 hours; OR
2. Increase in serum creatinine to $\ge 1.5\text{ times baseline}$, which is known or presumed to have occurred within the prior 7 days; OR
3. Urine volume $< 0.5\text{ mL/kg/h}$ for $\ge 6\text{ hours}$.

+-------------------------------------------------------------------------------------------------------+
|                                      KDIGO STAGING SYSTEM FOR AKI                                     |
|                                                                                                       |
|  Stage 1: Serum Cr 1.5–1.9x baseline OR increase >= 26.5 µmol/L (>=0.3 mg/dL) | UO <0.5 mL/kg/h for 6–12h|
|  Stage 2: Serum Cr 2.0–2.9x baseline                                          | UO <0.5 mL/kg/h for >=12h |
|  Stage 3: Serum Cr 3.0x baseline OR serum Cr >= 353.6 µmol/L (>=4.0 mg/dL)    | UO <0.3 mL/kg/h for >=24h |
|           OR initiation of Renal Replacement Therapy (RRT)                    | OR Anuria for >=12h       |
+-------------------------------------------------------------------------------------------------------+

Quantitative Definitions of Urine Output

• Normal Urine Output: $0.5\text{ to }1.5\text{ mL/kg/h}$ in adults (approximately $0.84\text{ to }2.52\text{ L/day}$ in a 70 kg individual).
• Oliguria: Urine output $< 0.5\text{ mL/kg/h}$ for $\ge 6\text{ consecutive hours}$ in adults, or a total 24-hour urine volume $< 400\text{ mL/day}$. Reflects inadequate volume to excrete the daily obligatory solute load (typically 500–600 mOsm/day).
• Anuria: Total 24-hour urine output $< 100\text{ mL/day}$.

  • Important

    Anuria is an emergency. Check catheter patency and bladder volume, assess circulation, and urgently investigate bilateral obstruction or obstruction of a solitary kidney/allograft. Severe renal hypoperfusion, major renal vascular occlusion and severe intrinsic injury are other important causes; urine volume alone does not distinguish them.

Diagnostic Classification of AKI: Pre-Renal, Intrinsic & Post-Renal

                                  [ ACUTE KIDNEY INJURY ]
                                             │
         ┌───────────────────────────────────┼───────────────────────────────────┐
         ▼                                   ▼                                   ▼
   [ PRE-RENAL AKI ]                 [ INTRINSIC AKI ]                   [ POST-RENAL AKI ]
   (Functional / Hemodynamic)        (Structural Parenchyma)             (Mechanical Obstructive)
   • Volume depletion, sepsis        • Acute Tubular Necrosis (ATN)      • Prostatic obstruction (BPH)
   • Cardiorenal / Hepatorenal       • Nephrotoxins (contrast, drugs)    • Bilateral ureteric stones
   • NSAIDs / ACEi / ARBs            • Interstitial nephritis, GN        • Solitary kidney block
   ──────────────────────────        ────────────────────────────        ──────────────────────────
   • FENa < 1%                       • ATN often FENa > 2%               • Dilated pelvicalyceal system
   • Urine Na < 20 mmol/L            • ATN often urine Na > 40 mmol/L      on renal ultrasound
   • Urine SG > 1.020                • ATN often SG ~ 1.010               • Emergent catheter/stent/PCN
   • BUN/Cr ratio > 20:1             • ATN: muddy brown casts            • Post-obstructive diuresis

Urinary indices below are typical supportive patterns, not diagnostic tests in isolation. Diuretics, CKD and sepsis can alter them, and haemodynamic and structural injury may coexist.

1. Pre-Renal AKI (Hemodynamic Azotemia)

• Etiology: Preserved parenchymal integrity with reduced renal perfusion pressure. Triggers include absolute intravascular hypovolemia (hemorrhage, gastrointestinal fluid losses, extensive burns, excessive diuresis), reduced effective circulating arterial volume (congestive heart failure [cardiorenal syndrome Type 1/2], advanced hepatic cirrhosis [hepatorenal syndrome], systemic distributive septic shock), or pharmacologically induced hemodynamic collapse:
  • NSAIDs: Inhibit cyclooxygenase (COX-1/2), blocking the synthesis of vasodilatory prostaglandins (PGE2, PGI2) at the afferent arteriole, triggering severe afferent vasoconstriction.
  • ACE Inhibitors / ARBs: Inhibit angiotensin II-mediated efferent arteriolar vasoconstriction, causing efferent vasodilation and an acute collapse of intraglomerular hydrostatic filtration pressure.
• Pathophysiology & Indices:
  • Intact tubular reabsorptive mechanisms avidly conserve water and sodium under maximal aldosterone and vasopressin stimulation.
  • Fractional Excretion of Sodium (FENa): $< 1\%$: $\text{FENa} (\%) = \frac{\text{Urine Na} \times \text{Serum Creatinine}}{\text{Serum Na} \times \text{Urine Creatinine}} \times 100$
  • Fractional Excretion of Urea (FEUrea): $< 35\%$ (may help when diuretics increase urinary sodium, but remains an adjunct to clinical assessment).
  • Urine Sodium Concentration: $< 20\text{ mmol/L}$.
  • Urine Specific Gravity: High ($> 1.020$); urine osmolality $> 500\text{ mOsm/kg}$.
  • BUN-to-Serum Creatinine Ratio: $> 20:1$ (both in mg/dL; the traditional SI urea-to-creatinine threshold is approximately $> 100:1$ when both use the same molar units), reflecting enhanced passive tubular reabsorption of urea alongside water in proximal tubules.
  • Urinary Microscopy: Bland sediment; occasional benign transparent hyaline casts.
• Therapeutic Response: Correct the cause: give isotonic crystalloid for volume depletion, optimize perfusion in shock, and treat congestion in volume-overloaded cardiorenal disease. Functional AKI often improves within 24–48 hours after appropriate correction; persistent dysfunction requires reassessment for structural injury.

2. Intrinsic (Renal) AKI

• Etiology:
  • Acute Tubular Necrosis (ATN; a common cause of intrinsic AKI):
    • Ischemic ATN: Prolonged, uncorrected pre-renal hypoperfusion resulting in ischemic death of tubular epithelial cells in the vulnerable straight S3 segment of the proximal tubule and thick ascending limb of Henle's loop.
    • Nephrotoxic ATN: Direct chemical toxicity from exogenous agents:
      • Aminoglycosides (gentamicin, amikacin): Cationic molecules that bind megalin receptors on proximal tubular brush borders, accumulate in lysosomes, and trigger necrosis (typically non-oliguric AKI appearing 5–7 days into therapy).
      • Iodinated Radiographic Contrast Media: Direct tubular cytotoxicity combined with intense medullary vasoconstriction (Contrast-Induced Nephropathy [CIN]).
      • Endogenous Toxins: Myoglobinuria from severe rhabdomyolysis (trauma, crush injuries, compartment syndrome, statin toxicity) inducing heme-pigment cast obstruction and free-radical generation; hemoglobinuria from intravascular hemolysis; and uric acid crystal nephropathy in acute tumor lysis syndrome.
  • Acute Interstitial Nephritis (AIN): Drug-induced hypersensitivity reaction (beta-lactams, fluoroquinolones, proton pump inhibitors, NSAIDs); may cause sterile pyuria, white cell casts and peripheral eosinophilia; eosinophiluria is neither sensitive nor specific.
  • Glomerulonephritis / Vasculitis: Presents with active urinary sediment (dysmorphic erythrocytes, erythrocyte casts), nephritic proteinuria, and systemic autoimmune markers.
• Typical ATN Pathophysiology & Indices:
  • Loss of tubular epithelial cell polarization, necrotic shedding into tubular lumens, and disruption of active sodium-potassium ATPase transport pumps destroy the kidney's ability to concentrate urine or retain sodium.
  • Fractional Excretion of Sodium (FENa): $> 2\%$.
  • Urine Sodium Concentration: $> 40\text{ mmol/L}$.
  • Urine Specific Gravity: Fixed at approximately $1.010$ (isosthenuria), reflecting loss of the corticomedullary osmotic gradient; urine osmolality $< 350\text{ mOsm/kg}$.
  • BUN-to-Serum Creatinine Ratio: Normal ($10:1\text{ to }15:1$).
  • Urinary Microscopy: Characteristic "muddy brown" granular casts, sloughed tubular epithelial cells, and coarse epithelial casts.

3. Post-Renal (Obstructive) AKI

• Etiology: Extrinsic or intraluminal mechanical obstruction to urinary outflow at any level below the renal collecting ducts:
  • Lower Tract Obstruction: Benign Prostatic Hyperplasia (BPH), prostate adenocarcinoma, urethral strictures, neurogenic bladder retention, or an occluded/malpositioned transurethral Foley catheter.
  • Upper Tract Obstruction: Bilateral ureteric obstruction or unilateral obstruction in a patient with a solitary functioning kidney or renal transplant. Causes include obstructing urolithiasis, bilateral retroperitoneal fibrosis (RPF / Ormond's disease), local invasion by pelvic malignancies (cervical, colorectal, bladder), or retroperitoneal lymphadenopathy.
• Diagnostic Evaluation:
  • Immediate Bedside Bladder Catheterization: Placement of a Foley catheter rapidly distinguishes lower tract retention from upper tract pathology. A large immediately drained volume confirms retention, but does not distinguish outlet obstruction from detrusor failure. A small bladder does not exclude upper-tract obstruction.
  • Renal Ultrasonography: The first-line radiological imaging modality. Exquisitely sensitive (>90%) for identifying bilateral pelvicalyceal dilation and measuring renal parenchymal thickness.
  • Critical Caveat: False-negative ultrasound examinations (minimal or absent hydronephrosis despite high-grade obstruction) occur in:
    1. Hyperacute obstruction (within the first 24 to 48 hours, before pelvicalyceal compliance permits structural dilation);
    2. Severe retroperitoneal fibrosis or malignant retroperitoneal encasement, where dense fibrous tissue physically constricts the ureters and prevents outward dilation;
    3. Severe volume depletion / dehydration.
• Emergency Decompression:
  • Lower tract: Transurethral Foley catheter or percutaneous suprapubic cystostomy.
  • Upper tract: Emergent retrograde Double-J ureteric stenting under cystoscopic guidance, or percutaneous nephrostomy tube (PCN) placement under ultrasound/fluoroscopy when retrograde passage is blocked.

Post-Obstructive Diuresis (POD)

Following successful decompression of prolonged bilateral urinary tract obstruction (or obstruction of a solitary kidney), patients frequently enter a state of post-obstructive diuresis.

• Definition: Sustained urine output exceeding $> 200\text{ mL/h}$ for 2 consecutive hours, or total 24-hour urine output $> 3\text{ L/day}$.
• Pathophysiological Mechanisms:
  1. Physiological / Solute Diuresis (Most Common): Excretion of retained urea, sodium, and excess free water that accumulated systemically during the obstructive interval. Acts as an endogenous osmotic diuretic.
  2. Pathological / Tubular Diuresis: Impaired tubular concentrating ability caused by transient medullary ischemia, down-regulation of collecting duct aquaporin-2 water channels, and blunted medullary responsiveness to vasopressin.
• Clinical Management:
  • Monitor vital signs, weight, fluid balance and hourly urine output. Check electrolytes and renal function frequently; severe diuresis or instability may require checks every 4–6 hours.
  • Correct hypovolaemia promptly. Once circulation is restored, a common starting strategy replaces 50–75% of recent urine losses, counting oral intake and adjusting IV fluid composition to serum sodium, potassium and clinical balance.
  • Avoid unnecessary over-replacement in a patient shedding retained salt and water. Persistent salt-wasting or hypovolaemia may require more fluid; replace potassium only according to measured levels and renal function. Taper support as diuresis resolves.

Urgent Indications for Renal Replacement Therapy: The "AEIOU" Mnemonic

When medical management fails to arrest biochemical or physiological deterioration, emergent renal replacement therapy (intermittent hemodialysis or continuous renal replacement therapy [CRRT]) must be instituted. The AEIOU mnemonic identifies major indications. Decisions depend on life-threatening complications, response to treatment and trends, rather than a single creatinine, urea, pH or potassium cutoff:

+-------------------------------------------------------------------------------------------------------+
|                                URGENT INDICATIONS FOR DIALYSIS: "AEIOU"                               |
|                                                                                                       |
|  A - ACIDOSIS       --> Severe refractory metabolic acidosis (e.g., pH < 7.15–7.20)                   |
|                         unresponsive to medical alkalinization                                         |
|  E - ELECTROLYTES   --> Severe refractory hyperkalaemia (K+ > 6.5 mmol/L) or rapid rise with ECG      |
|                         changes (peaked T waves, wide QRS, sine-wave) refractory to medical treatment  |
|  I - INGESTIONS     --> Severe poisoning: Methanol, Ethylene glycol, Lithium, Salicylates             |
|  O - OVERLOAD       --> Refractory volume overload / pulmonary edema unresponsive to loop diuretics    |
|  U - URAEMIA        --> Uremic encephalopathy (confusion, asterixis, seizures), uremic pericarditis    |
|                         (friction rub; ABSOLUTE indication; HEPARIN-FREE DIALYSIS MANDATORY),          |
|                         or uremic coagulopathy with active hemorrhage                                 |
+-------------------------------------------------------------------------------------------------------+

• A - Acidosis: Severe persistent metabolic acidosis despite appropriate treatment, especially with circulatory compromise or fluid overload. Values such as $\text{pH} < 7.15–7.20$ describe severe acidosis, but KDIGO specifies no universal pH or bicarbonate threshold for starting RRT.
• E - Electrolytes: Severe hyperkalaemia (often $[\text{K}^+] > 6.5\text{ mmol/L}$), particularly with ECG toxicity, requires immediate treatment and renal/critical-care review:
  • Cardiac protection for hyperkalaemic ECG changes: ERC/RCUK 2025 recommends 10 mL 10% calcium chloride IV over 5 minutes, or 30 mL 10% calcium gluconate over 10 minutes if calcium chloride is unavailable. Calcium protects the myocardium without lowering potassium.
  • Intracellular shifting: 10 units soluble insulin IV with 25 g glucose (e.g., 50 mL 50% glucose), with glucose monitoring; nebulized salbutamol 10–20 mg is an adjunct. Additional glucose infusion may be needed to prevent hypoglycaemia.
  • Removal: Sodium zirconium cyclosilicate may assist potassium removal. Binders do not replace immediate cardiac protection or shifting therapy; older polystyrene resins are unsuitable as emergency rescue treatment.
  • Arrange urgent RRT for persistent life-threatening hyperkalaemia despite medical therapy, continuing temporizing treatment while dialysis is prepared.
• I - Ingestions / Intoxications: Severe poisoning with dialyzable substances, including methanol, ethylene glycol, lithium, salicylates and severe metformin-associated lactic acidosis. Dialysis depends on toxin-specific concentrations, acid-base disturbance, organ dysfunction and response to antidotes/supportive care; ingestion alone is not an indication.
• O - Overload: Severe refractory hypervolemia, congestive heart failure, or acute flash pulmonary edema unresponsive to escalating doses of intravenous loop diuretics (e.g., furosemide bolus plus continuous infusion).
• U - Uraemia: Clinical manifestations of severe azotemia:
  • Uremic Encephalopathy: Cognitive decline, confusion, somnolence, asterixis (metabolic flapping tremor), myoclonus, or seizures.
  • Uremic Pericarditis: Suspect this in severe renal failure with a pericardial friction rub or chest pain; assess other causes and obtain echocardiography for effusion/tamponade. It carries an acute risk of progression to hemorrhagic pericardial effusion, cardiac tamponade, and hemodynamic collapse. Uremic pericarditis is an absolute indication for immediate dialysis.

    • [!CRITICAL] HEPARIN-FREE DIALYSIS IS MANDATORY IN UREMIC PERICARDITIS: Systemic heparinization during hemodialysis can precipitate catastrophic intrapericardial hemorrhage into the inflamed pericardial space, inducing fatal cardiac tamponade. Dialysis must be conducted without heparin or using regional citrate anticoagulation.

  • Uremic Coagulopathy: Uremic toxins induce functional platelet dysfunction (defective GPIIb/IIIa receptor activation and impaired interaction with von Willebrand factor), leading to mucosal bleeding or surgical wound hemorrhage. Temporized acutely with DDAVP (desmopressin 0.3 µg/kg IV) or cryoprecipitate while preparing for emergent dialysis.

Chronic Kidney Disease (CKD) & Perioperative Renoprotection

CKD requires abnormalities of kidney structure or function for at least 3 months. Classify by cause, GFR category G1–G5 and albuminuria category A1–A3; G1/G2 require another marker of kidney damage, whereas eGFR $<60\text{ mL/min/1.73 m}^2$ defines G3–G5. Urological interventions require perioperative care to prevent acute-on-chronic injury:

• Hemodynamic Stability: Maintain euvolemia and preserve mean arterial pressure ($\text{MAP} \ge 65–70\text{ mmHg}$) during anaesthesia to maintain adequate renal perfusion pressure.
• Avoidance of Nephrotoxic Insults: Strictly avoid NSAIDs for postoperative analgesia; substitute with paracetamol, regional blocks, and judicious opioids.
• Rational Antibiotic Selection & Dosing: Adjust dosages of renally excreted antimicrobials (aminoglycosides, vancomycin, fluoroquinolones, cephalosporins) using the renal-function estimate specified for the drug: Cockcroft-Gault estimates creatinine clearance, whereas CKD-EPI estimates GFR. In evolving AKI, estimates are unreliable; use clinical trends and drug levels where appropriate.
• Contrast Renoprotection: Use low/iso-osmolar contrast at the lowest diagnostic dose. ESUR identifies AKI or eGFR $<30\text{ mL/min/1.73 m}^2$ as major risk settings for IV contrast (higher threshold for first-pass intra-arterial exposure). Give preventive IV hydration when indicated, individualized for heart failure/fluid overload; do not automatically hydrate every CKD patient or delay essential emergency imaging.
• Preparation for Transplantation: In patients with progressive CKD approaching end-stage disease (eGFR $< 15–20\text{ mL/min/1.73 m}^2$), timely evaluation for living-donor or deceased-donor renal transplantation—ideally pre-emptive transplantation prior to the initiation of chronic maintenance dialysis—confers the highest long-term patient survival and graft longevity.

---

2. Surgical Implantation Technique

Renal allografts are typically positioned heterotopically in the recipient's iliac fossa within the extraperitoneal space.

Choice of Iliac Fossa

• The right iliac fossa is often chosen for first-time implantation, although either iliac fossa is acceptable; vessel quality, graft anatomy and prior surgery determine the choice:
  • The right external iliac vein lies relatively superficial, horizontal, and easily accessible lateral to the pelvic brim.
  • Conversely, the left external iliac vein runs deep, medial, and posterior to the left external iliac artery, requiring more extensive mobilization.
  • The sigmoid colon occupies the left iliac fossa, which can crowd the retroperitoneal space.

Vascular Anastomoses

• Venous Anastomosis: The donor renal vein is anastomosed end-to-side to the recipient's external iliac vein using a 5-0 or 6-0 non-absorbable monofilament polypropylene (Prolene) continuous suture. In deceased donor right kidneys, an extension cuff from the donor inferior vena cava is frequently harvested to lengthen the short right renal vein.
• Arterial Anastomosis:
  • In deceased donor kidneys, the donor renal artery is harvested with an elliptical Carrel aortic patch and anastomosed end-to-side to the recipient's external iliac artery.
  • In living donor kidneys (where an aortic Carrel patch cannot be taken), the single renal artery is anastomosed end-to-side to the external iliac artery or end-to-end to the internal iliac (hypogastric) artery.

Urinary Reconstruction: Lich-Gregoir Ureteroneocystostomy

• Lich-Gregoir Extravesical Technique (Gold Standard):
  • Performed entirely extravesically without opening the main bladder lumen.
  • The detrusor muscle on the anterolateral bladder wall is incised for 3 to 4 cm down to the intact, bulging urothelial mucosa.
  • A tiny 5 mm mucosal incision is made at the distal end of the trough.
  • The spatulated distal donor ureter is anastomosed mucosa-to-mucosa using fine absorbable suture (5-0 or 6-0 PDS/polydioxanone).
  • The detrusor muscle flaps are then closed over the ureter with interrupted sutures, creating a submucosal anti-reflux tunnel with an approximate 3:1 length-to-diameter ratio.
• Intravesical Technique (Politano-Leadbetter): Involves anterior cystotomy, pull-through of the ureter into the bladder, and submucosal tunneling. It is an alternative reconstruction; the extravesical approach is generally favoured for its lower urological complication burden.
• Routine Internal Double-J Stenting: Meta-analyses and EAU guidelines establish that routine placement of an internal Double-J ureteric stent during ureteroneocystostomy reduces the incidence of major urological complications (urinary leaks and early obstruction) by over 60% (odds ratio ~0.24). Stents are typically removed cystoscopically under local anaesthesia at 4 to 6 weeks post-transplant.

---

3. Immunosuppressive Regimens

Successful allograft maintenance balances prevention of acute rejection against the risks of calcineurin inhibitor nephrotoxicity, opportunistic infections (cytomegalovirus, BK polyomavirus, Pneumocystis jirovecii), and de novo malignancies.

Induction Regimens

Administered intraoperatively and during the first postoperative days to provide intense initial T-cell suppression:

1. Interleukin-2 Receptor Antagonist (IL-2RA; Basiliximab):
   • Monoclonal antibody against the CD25 alpha-subunit of the IL-2 receptor on activated T lymphocytes.
   • Indication: Standard / low-to-moderate immunological risk recipients.
   • Dosing: Non-depleting antibody; administered on Day 0 and Day 4.
2. T-Cell Depleting Antibodies (Antithymocyte Globulin - ATG / Thymoglobulin):
   • Polyclonal antibody inducing profound, prolonged T-lymphocyte lysis via complement-mediated clearance.
   • Indication: High immunological risk recipients, assessed using sensitization (PRA/DSA), transplant history and other recipient factors. DCD/prolonged cold ischaemia increase delayed graft-function risk and may influence the regimen, but do not themselves establish high immunological risk.
   • Plan CMV prevention according to donor/recipient serostatus and immunosuppression: antiviral prophylaxis or monitored pre-emptive therapy. Provide Pneumocystis prophylaxis, commonly trimethoprim-sulfamethoxazole.

Maintenance Triple Therapy

The standard maintenance regimen combines three agents with complementary mechanisms of action:

+-------------------------------------------------------------------------------------------------------+
|                                STANDARD TRIPLE MAINTENANCE IMMUNOSUPPRESSION                          |
|                                                                                                       |
|  1. Calcineurin Inhibitor (CNI)   --> TACROLIMUS (FK506) [Preferred over Cyclosporine]                |
|                                       Inhibits NFAT dephosphorylation and IL-2 transcription          |
|  2. Antimetabolite                --> MYCOPHENOLATE MOFETIL (MMF) / Mycophenolic Acid (MPA)           |
|                                       Inhibits IMPDH, blocking de novo purine synthesis in T/B cells  |
|  3. Corticosteroid                --> PREDNISOLONE (tapered to low maintenance, e.g., 5 mg/day)       |
+-------------------------------------------------------------------------------------------------------+

Calcineurin Inhibitor Nephrotoxicity and Therapeutic Monitoring

Tacrolimus is the cornerstone of maintenance immunosuppression, but has a narrow therapeutic window:

• Acute CNI Nephrotoxicity: Dose-dependent, hemodynamically mediated reversible vasoconstriction of the afferent glomerular arteriole. Causes an acute rise in serum creatinine, hypertension, hyperkalemia, and hypomagnesemia; the acute functional component can improve after dose adjustment.
• Chronic CNI Nephrotoxicity: Irreversible structural injury characterized histologically by obliterative arteriopathy (hyalinosis of afferent arterioles), "striped" interstitial fibrosis, tubular atrophy, and secondary glomerulosclerosis.
• Therapeutic Drug Monitoring (TDM): Measure whole-blood trough immediately before the next dose: approximately 12 hours for twice-daily immediate-release tacrolimus and 24 hours for once-daily prolonged-release formulations. Targets depend on transplant phase, rejection risk and centre protocol; one commonly used example is:
  • Months 1–3: Target trough 8 to 12 ng/mL.
  • Months 3–12: Target trough 6 to 8 ng/mL.
  • Maintenance (>12 months): Target trough 5 to 7 ng/mL.

---

4. Post-Transplant Urological & Vascular Complications

Urological and vascular complications occur in 4% to 10% of kidney transplant recipients and are a significant source of graft-threatening morbidity.

1. Ureteral Obstruction (Incidence: 2%–5%)

• Etiology:
  • Early Obstruction (<3 months): Distal ureteric ischaemia, technical narrowing/kinking, extrinsic haematoma or intraluminal clot.
  • Late Obstruction: Fibrosis associated with infection, rejection or vascular disease may cause later strictures. Ischaemia is not confined to late presentation: the native ureter has segmental arterial contributions from renal, gonadal and pelvic vessels, whereas the donor ureter depends on renal arterial branches in its peri-ureteral tissue. Preserve this tissue during procurement and implantation.
• Clinical Presentation: Asymptomatic rise in serum creatinine, or graft hydronephrosis discovered on surveillance ultrasound (obstruction is often painless because the allograft is denervated).
• Diagnostic and Management Pathway:
  1. Ultrasound detects hydronephrosis; persistent dilatation with impaired graft function raises concern for a clinically significant stricture.
  2. Percutaneous Nephrostomy (PCN): The immediate first step to decompress the allograft, followed by an antegrade pyelogram (nephrostogram) to identify the exact location and length of the stricture.
  3. Endourological Management: Short strictures (<1–2 cm) can be managed with antegrade balloon dilation and placement of a Double-J stent, with success rates of ~50%.
  4. Open Surgical Reconstruction (Definitive Gold Standard): For long or refractory strictures:
     • Re-ureteroneocystostomy with a Boari flap or Psoas hitch if bladder mobilization is required.
     • Ureteroureterostomy to the Native Ipsilateral Ureter: The distal stenotic donor ureter is excised, and the healthy proximal allograft ureter (or renal pelvis) is anastomosed end-to-end or end-to-side to the recipient's native ipsilateral ureter. A healthy recipient ureter is a useful reconstructive option; choose the repair according to viable tissue, defect length and bladder suitability.

2. Urinary Leak / Urinoma (Incidence: 1%–3%)

• Etiology: Most frequently occurs within the first 1 to 2 weeks post-transplant due to ischemic necrosis of the distal-most tip of the donor ureter, or dehiscence of the cystostomy suture line.
• Clinical Presentation: Oliguria, localized graft pain/swelling, wound drainage, or fluid collection around the allograft on ultrasound.
• Diagnostic Confirmation: Fluid collection aspiration and biochemical analysis:

  • Important

    The fluid creatinine concentration must be compared directly against concurrent serum creatinine.

    • A fluid creatinine clearly above concurrent serum creatinine supports a urinary leak; no fixed 10- to 50-fold ratio is required.
    • Fluid creatinine similar to serum favours lymphocele/seroma; interpret with timing, fluid appearance and imaging, rather than diagnosing the collection from creatinine alone.
• Management:
  • Small, Contained Leaks: Managed conservatively with maximal decompression: retrograde or antegrade Double-J ureteric stenting, percutaneous drain placement into the urinoma, and prolonged transurethral Foley catheter drainage for 2 to 3 weeks.
  • Large Leaks or Complete Distal Necrosis: Mandatory open surgical re-exploration. Debride the necrotic distal ureter and perform re-implantation with a psoas hitch or native-to-donor ureteroureterostomy.

3. Vascular Complications

• Transplant Renal Artery Stenosis (TRAS; Incidence: 5%–10%):
  • Occurs 3 months to 2 years post-transplant, most frequently at the vascular anastomosis.
  • Clinical Triad: Refractory, worsening systemic hypertension requiring multiple antihypertensives; unexplained graft dysfunction; and sudden drop in GFR following initiation of an ACE inhibitor or Angiotensin Receptor Blocker (ARB).
  • First-Line Assessment: Color Doppler ultrasound may demonstrate a Peak Systolic Velocity (PSV) > 2.0 to 2.5 m/s at the stenosis, parvus-tardus waveform in intrarenal interlobar arteries (slow acceleration time $>0.07 \text{ s}$), and a renal-to-iliac artery velocity ratio $>1.8$. Confirmed by CT Angiography or Digital Subtraction Angiography (DSA).
  • Management: Mild stenosis without graft dysfunction or uncontrolled hypertension may be monitored medically. For clinically significant stenosis, PTA with or without stenting is usually first-line when feasible; surgical revision is considered for unsuitable anatomy, recent/complex stenosis or failed endovascular treatment.
• Transplant Renal Vein Thrombosis (TRVT; Incidence: 0.5%–2%):
  • Most common within the first 48 hours to 2 weeks post-transplant.
  • Presentation: Sudden, severe graft pain, gross hematuria, massive graft swelling, and sudden abrupt anuria.
  • Doppler Ultrasound: Absent venous flow with reversed arterial diastolic flow strongly suggests venous thrombosis. Reversed arterial flow alone is not specific and can occur with severe rejection, ATN or vascular compression/kinking.
  • Prognosis: Catastrophic complication; graft loss exceeds 80%–90%. Requires emergency re-exploration: attempt thrombectomy in a viable graft; perform nephrectomy if the graft is non-viable.

4. Lymphocele (Incidence: 5%–15%)

• Etiology: Extraperitoneal collection of lymphatic fluid resulting from severed, unligated recipient iliac lymphatic channels divided during iliac vessel mobilization, or divided donor allograft hilar lymphatics.
• Presentation: Typically emerges 2 to 8 weeks post-transplant. Most are small and asymptomatic. Large lymphoceles cause mass effect: external compression of the allograft ureter causing hydronephrosis, or compression of the external iliac vein causing ipsilateral leg edema and deep vein thrombosis (DVT).
• Diagnosis: Ultrasound reveals an anechoic, septated fluid collection. Aspiration confirms lymphatic fluid (creatinine similar to serum, with lymphocyte predominance; exclude urine, blood and infection).
• Management:
  • Small asymptomatic collections: Observation.
  • Large symptomatic or obstructive lymphoceles: Percutaneous catheter drainage is first-line; selected cases may also receive sclerotherapy. Simple needle aspiration alone has a high recurrence rate. If percutaneous treatment fails, perform laparoscopic peritoneal fenestration (marsupialization), creating a wide window into the peritoneal cavity for lymphatic fluid absorption.

Renal Failure Work-up, Dialysis Criteria & Transplant Complications Matrix